Efficacy
liver cancer, PD
PATHOLOGY, PROGRESSIVE DISEASE, LIVER CANCER, DISEASE, DISEASE
As of September 28, 2022, the median duration of follow-up was 13.6 (0.83-24.9) months. A total of 34 patients (39.1%) died, and the median OS was not reached. The OS rates of 6, 12 and 18 months were 84.6%, 73.4% and 55.2%, respectively (Progression-free survival in the all patients by the Kaplan Meier method per RECIST v1.1.Response to combined therapy.CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; NE, Not evaluable; ORR, Objective response rate; DCR, Disease control rate.The best change from baseline in the sum of the target lesion diameter per patient. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.Imaging data and postoperative pathology of a 55-year-old male patient with advanced liver cancer after successful conversion therapy. 
Subgroup analysis of objective response rate according to baseline characteristics.Subgroup analysis of progression-free survival according to baseline characteristics.